Abstract Library

#2730 FOLFIRINEC, A Multi-Center, Randomized, Comparative Phase II Study of FOLFIRINOX vs Platinum-Etoposide as First Line Treatment for Metastatic Neuroendocrine Carcinoma of Gastroenteropancreatic or Unknown Origin, Associated with Molecular Profiling

Introduction: Grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine carcinoma (NEC) are rare diseases with a poor prognosis. FOLFIRINEC is a multicenter comparative phase II study of mFOLFIRINOX vs platinum-etoposide (PE) as first line treatment for metastatic G3 NEC of GEP or unknown origin.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hadoux J

Authors: Hadoux J, Afchain P, Walter T, Tougeron D, Hautefeuille V,

Keywords: neuroendocrine carcinoma, gastroenteropancreatic, chemotherapy, FOLFIRINOX, RB,

#1189 European Information Network on Rare Cancers (RARECAREnet)

Introduction: NETs are considered as a rare cancer. Because of the complexity and the different disciplines involved, a multidisciplinary approach is desirable. The referral to centres of expertise (CoE) is indicated as the optimal strategy for effective management.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Van der Zwan J

Authors: Van der Zwan J, Trama A, Capoccacia R, Gatta G, Siesling S,

Keywords: Registry,

#829 On the Benign Side of Malignancy: How Neuroendocrine Tumors are Experienced by Patients and Their Family Carers

Introduction: Neuroendocrine tumors (NETs) are rare, slow-growing neoplasia with variable clinical presentations. Due to their non-specific symptoms and a lack of diagnostic tools, late diagnosis is common. There is little research relating to NETs as experienced by both patients and family carers.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Kall S

Authors: Kall S, Spichiger E, Stoll H,

Keywords: neuroendocrine tumors, rare diseases, qualitative research ,